查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1624425

全球病毒清除市場規模（按方法、應用程式、最終用戶、地區、範圍和預測）

Global Viral Clearance Market Size By Method, By Application, By End-User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

病毒清除市場規模及預測

預計2024年病毒清除市值為6.2837億美元，預計2024年至2031年期間複合年增長率為12.21%，到2031年將達到14.5527億美元。

病毒清除的全球市場推動因素

病毒清除市場的市場推動因素可能會受到多種因素的影響。

對生物製藥的需求不斷增加：

生物製藥的需求也同時增加，需要實施嚴格的病毒清除程序以確保產品安全。基因療法、疫苗和單株抗體等生物製藥經常含有生物物質，因此清除病毒至關重要，以防止病毒污染物的傳播。

嚴格的監理義務：

歐洲藥品管理局（EMA）、美國食品藥物管理局（FDA）等監管機構對生物製藥生產中的病毒清除制定了嚴格的標準。遵守這些規定是我們引入尖端病毒清除技術和服務的動力。

病毒感染增加：

病毒感染的增加，包括肝炎、愛滋病毒/愛滋病以及伊波拉和寨卡等新出現的病毒，凸顯了實施有效的病毒清除策略的重要性。在這樣的發展背景下，必須不斷改進病毒清除技術，以對抗不斷變化的病毒威脅。

生物製程開發：

生物加工技術的進步，包括淨化、細胞培養和分析測定，有助於提高病毒清除能力。這些發展使生物製藥公司能夠提高其病毒清除程序的有效性和可靠性。

生物製造業的成長：

病毒清除解決方案的需求受到生物製造業擴張的推動，這受到新型生物製劑和生物相似藥發展的推動。與生物製藥市場的預期成長軌跡類似，病毒清除市場也預計將持續擴大。

增加病毒清除服務的外包：

生物製藥行業越來越多地將病毒清除測試和驗證的責任委託給專門的合約研究組織 (CRO) 和合約製造組織 (CMO)。對病毒清除活動中的專業知識、基礎設施和成本效益的需求是推動這種外包趨勢的因素。

新興的病毒清除技術：

新型病毒清除技術的出現是正在進行的研究和開發的主題。這些技術旨在提高功效、速度和成本效益。色譜技術、病毒滅活技術和下一代過濾方法等技術創新正在推動市場擴張。

製藥製造業的全球化：

製藥製造的全球化是不同地區廣泛實施標準化病毒清除程序的關鍵推動因素。在多個國家運營的組織努力遵守全球監管規範，因此世界各地對病毒清除解決方案產生了濃厚的興趣。

限制全球病毒清除市場的因素

有幾個因素可能會對病毒清除市場造成限制和課題。

嚴格的監理要求：

嚴格的監管要求：監管機構有嚴格的指導方針和標準，以確保生物製劑的病毒清除。這可能會促使更長的開發和審批流程以及增加成本。

病毒清除程式成本高：

病毒清除程序通常需要使用複雜的技術和設備，其購買和維護成本很高。由於成本過高，較小的組織和企業可能不願意進入這個市場。

病毒清除程式的複雜性：

與病毒清除相關的課題病毒清除程序可能很困難並且需要專業知識。在嘗試設計和實施有效的病毒清除策略時，組織可能會遇到困難。

產品污染風險：

儘管實施了嚴格的病毒清除協議，但產品污染仍然存在可能性，從而促使昂貴的產品召回和聲譽損害。

可擴充性限制：

某些病毒清除方法可能難以滿足大規模生產的要求，尤其是對於高產量生物製藥產品而言。

新的病毒威脅：

病毒根除策略面臨病毒不斷演化帶來的課題。新出現或新型病毒的出現可能需要開發新的控制方法，從而增加市場的複雜性和不可預測性。

與替代技術的衝突：

替代技術相對於傳統病毒清除方法的脆弱性意味著它們可能面臨旨在滅活或去除病毒的過濾和熱處理等技術的競爭。

道德與安全考量：

使用某些含有潛在危險化合物或動物源產品的病毒清除方法可能會引發倫理問題。

目錄

第 1 章 全球病毒清除市場簡介

    市場概況
  • 研究範圍
  • 先決條件

第 2 章執行摘要

第 3 章：經過驗證的市場研究方法

  • 資料探勘
  • 驗證
  • 主要來源
  • 資料來源列表

第 4 章 全球病毒清除市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 阻礙因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第 5 章全球病毒清除市場（依方法論）
  • 概述
  • 病毒清除
  • 病毒滅活

第6章 全球病毒清除市場（按應用）

  • 概述
  • 重組蛋白
  • 血液和血液製品
  • 疫苗
  • 其他

第7章 全球病毒清除市場（按最終用戶）

  • 概述
  • 製藥和生技公司
  • 合約研究組織
  • 學術研究機構
  • 其他

第8章 全球病毒清除市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
    亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

第 9 章全球病毒清除市場的競爭格局

  • 概述
  • 各公司的市場排名
  • 主要發展策略

第10章 公司簡介

  • Charles River Laboratories International
  • Merck KGaA
  • Wuxi Biologics（Cayman）（Subsidiary of Wuxi Apptec）
  • Texcell
  • Kedrion
  • Bsl Bioservice
  • Vironova Biosafety
  • Clean Cells
  • Virusure GmbH

第11章 附錄

  • 關聯調查
簡介目錄
Product Code: 24294

Viral Clearance Market Size And Forecast

Viral Clearance Market size was valued at USD 628.37 Million in 2024 and is projected to reach USD 1455.27 Million by 2031 , growing at a CAGR of 12.21% during the forecasted period 2024 to 2031.

Global Viral Clearance Market Drivers

The market drivers for the Viral Clearance Market can be influenced by various factors. These may include: Increasing Demand for Biopharmaceuticals:

The demand for biopharmaceuticals is experiencing a concurrent increase, necessitating the implementation of rigorous viral clearance procedures to guarantee the safety of the products. Biopharmaceuticals, such as gene therapies, vaccines, and monoclonal antibodies, frequently incorporate biological substances; therefore, viral clearance is of the utmost importance in order to avert the spread of viral contaminants.

Strict regulatory obligations:

Regulatory agencies, including the European Medicines Agency (EMA) in Europe and the Food and Drug Administration (FDA) in the United States, impose rigorous criteria for viral clearance in the manufacturing of biopharmaceuticals. Compliance with these regulations motivates the implementation of cutting-edge technologies and services for viral clearance.

An increasing prevalence of viral infections:

The growing incidence of viral infections, including hepatitis, HIV/AIDS, and emergent viruses such as Ebola and Zika, highlights the criticality of implementing efficient viral clearance strategies. On account of this development, ongoing advancements in viral clearance technologies are required to combat the ever-changing viral threats.

Developments in Bioprocessing Methods:

Bioprocessing technological advancements, such as methods for purification, cell culture, and analytical assays, contribute to enhanced viral clearance capabilities. These developments empower biopharmaceutical firms to improve the effectiveness and dependability of viral clearance procedures.

Growing Biomanufacturing Sector:

Growing The demand for viral clearance solutions is fueled by the expanding biomanufacturing sector, which is propelled by the development of novel biologics and biosimilars. Consistent with the anticipated growth trajectory of the biopharmaceutical market, the viral clearance market is anticipated to experience ongoing expansion.

Increasing Outsourcing of Viral Clearance Services:

A growing trend in the biopharmaceutical industry is the delegation of viral clearance testing and validation responsibilities to specialized contract research organizations (CROs) and contract manufacturing organizations (CMOs). In viral eradication activities, the demand for specialized knowledge, infrastructure, and cost-efficiency motivates this outsourcing trend.

Emergence of Novel Viral Clearance Technologies:

The emergence of novel viral clearance technologies is the subject of ongoing research and development. These technologies aim to provide enhanced effectiveness, velocity, and cost-effectiveness. Market expansion is aided by innovations including chromatography techniques, viral inactivation technologies, and filtration methods of the next generation.

Globalization of Pharmaceutical Manufacturing:

The globalization of pharmaceutical manufacturing is a significant factor in the widespread implementation of standardized viral clearance procedures in various geographic areas. Organizations that have operations in numerous nations strive to conform to global regulatory norms, which has generated significant interest in viral clearance solutions worldwide.

Global Viral Clearance Market Restraints

Several factors can act as restraints or challenges for the Viral Clearance Market. These may include:

Stringent Regulatory Requirements:

Regulatory bodies enforce rigorous guidelines and criteria to ensure the viral clearance of biological products. This can result in extended development and approval processes, as well as increased costs.

High Cost of Viral Clearance Procedures:

Viral clearance procedures frequently necessitate the use of sophisticated technology and apparatus, the acquisition and upkeep of which can be quite costly. Smaller organizations or corporations may be dissuaded from entering the market by the exorbitant expense.

Complexity of Viral Clearance Procedures:

Difficulties Associated with Viral Clearance Procedures for viral clearance can be difficult and demand specialized knowledge. Organizations might encounter difficulties when attempting to devise and execute efficient viral clearance strategies.

Risk of Product Contamination:

Notwithstanding the implementation of stringent viral clearance protocols, the potential for product contamination remains, resulting in expensive product recalls and reputational harm.

Scalability Constraints:

Certain viral clearance methods might present challenges in accommodating the requirements of large-scale production, especially in the case of biopharmaceuticals with substantial volume of output.

Emerging Viral Threats:

Viral eradication strategies face a challenge posed by the perpetual evolution of viruses. Emerging viruses or new viral variants may necessitate the development of novel clearance methods, thereby increasing market complexity and unpredictability.

Competition from Alternative Technologies:

Alternative Technologies Vulnerabilities to Traditional Viral Elimination Methods may face competition from technologies such as filtration or thermal treatment that aim to inactivate or eliminate viruses.

Ethical and Safety Considerations:

The utilization of specific viral clearance methods that incorporate potentially hazardous compounds or animal-derived products may give rise to ethical concerns.

Global Viral Clearance Market: Segmentation Analysis

The Global Viral Clearance Market is Segmented on the basis of Method, Application, End-User, And Geography.

Viral Clearance Market, By Method

  • Viral Removal
  • Viral Inactivation

Based on the Method, The market is bifurcated into Viral Removal and Viral Inactivation. The Viral Removal segment is expected to hold the largest market share. The factors can be attributed to the high acceptance of this method, the growth of R&D activities by biopharmaceutical companies, and the accuracy, speed, & flexibility provided by the method in life sciences research.

Viral Clearance Market, By Application

  • Recombinant Proteins
  • Blood and Blood Products
  • Vaccines
  • Others

Based on the Application, The market is bifurcated into Recombinant Proteins, Blood and Blood Products, Vaccines, and Others. The other segment is predicted to hold the most significant CAGR in the forecasted period due to the growing public & private funding for stem cell research, the use of tissue-based therapies to treat various diseases, and the rising use of cellular therapies in the treatment of various disorders.

Viral Clearance Market, By End-User

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic Research Institutes
  • Others

Based on End-User, The market is bifurcated into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes, and Others. The Contract Research Organizations segment is anticipated to hold the largest market share. The factors can be credited for the increasing outsourcing of Drug Discovery Services to CROs by pharmaceutical companies, academic institutes, small biotechnology companies, & start-ups and the ability of CROs to invest in extensive drug discovery infrastructure.

Viral Clearance Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Regional Analysis, The Global Viral Clearance Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America owing to growth in the pharmaceuticals industry, rising number of drug approvals, and the presence of national institutes supporting biotechnology and life science research in this region.

Key Players

  • Charles River Laboratories International
  • Merck KGaA
  • Wuxi Biologics (Cayman) (Subsidiary of Wuxi Apptec)
  • Texcell
  • Kedrion
  • Bsl Bioservice
  • Vironova Biosafety
  • Clean Cells Virusure GmbH

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL VIRAL CLEARANCE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL VIRAL CLEARANCE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL VIRAL CLEARANCE MARKET, BY METHOD

  • 5.1 Overview
  • 5.2 Viral Removal
  • 5.3 Viral Inactivation

6 GLOBAL VIRAL CLEARANCE MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Recombinant Proteins
  • 6.3 Blood and Blood Products
  • 6.4 Vaccines
  • 6.5 Others

7 GLOBAL VIRAL CLEARANCE MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Pharmaceutical & Biotechnology Companies
  • 7.3 Contract Research Organizations
  • 7.4 Academic Research Institutes
  • 7.5 Others

8 GLOBAL VIRAL CLEARANCE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL VIRAL CLEARANCE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Charles River Laboratories International
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Merck KGaA
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Wuxi Biologics (Cayman) (Subsidiary of Wuxi Apptec)
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Texcell
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Kedrion
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Bsl Bioservice
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Vironova Biosafety
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Clean Cells
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Virusure GmbH
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments

11 Appendix

  • 11.1 Related Research